Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer

Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancer

Abstract Even when targets responsible for chemoresistance are identified, drug development is often hampered due to the poor druggability of these proteins. We systematically analyzed therapy-resistance with a large-scale cancer cell transcriptome and drug-response datasets and predicted the candid...

Full description

Bibliographic Details
Main Authors: Soon-Ki Hong, Haeseung Lee, Ok-Seon Kwon, Na-Young Song, Hyo-Ju Lee, Seungmin Kang, Jeong-Hwan Kim, Mirang Kim, Wankyu Kim, Hyuk-Jin Cha
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Molecular Cancer
Subjects:
Chemoresistance
Mesenchymal cancer
Pharmacogenomics
Drug repurposing
Biomarker
ITGB3
Online Access:http://link.springer.com/article/10.1186/s12943-018-0924-8

Internet

http://link.springer.com/article/10.1186/s12943-018-0924-8

Similar Items